Poxel S.A., a clinical-stage biopharmaceutical company headquartered in Lyon, France, continues to make significant strides in the biotechnology sector, particularly within the health care industry. As of April 30, 2026, Poxel S.A. remains focused on developing innovative treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases, including rare metabolic disorders and associated steatohepatitis.
The company’s lead product, TWYMEEG (Imeglimin), an oral drug candidate targeting mitochondrial dysfunction, has achieved a notable milestone with its approval for the treatment of type 2 diabetes in Japan. This approval underscores Poxel’s commitment to addressing unmet medical needs in metabolic diseases. Imeglimin’s development and commercialization are supported by a strategic partnership with Sumitomo Pharma, highlighting the collaborative efforts to bring this promising treatment to a broader market.
In addition to Imeglimin, Poxel is advancing its pipeline with PXL770, an adenosine monophosphate-activated protein kinase enzyme inhibitor currently in a Phase 2a clinical trial. This candidate is being evaluated for its potential to treat chronic metabolic diseases, including non-alcoholic steatohepatitis (NASH), a condition that affects the liver and is associated with significant morbidity.
Poxel’s innovative approach extends to PXL065, an earlier-stage program in Phase 2 clinical trials, focusing on the treatment of NASH and other chronic and rare metabolic indications. This program is being developed in collaboration with DeuteRx LLC, emphasizing Poxel’s strategic alliances to enhance its research and development capabilities.
Furthermore, Poxel has entered into a licensing agreement with Enyo Pharma S.A.S. for the development of a farnesoid X receptor, which is currently in a Phase 2a study targeting hepatitis B and NASH. This agreement reflects Poxel’s dedication to exploring novel therapeutic pathways and expanding its portfolio of potential treatments for liver diseases.
Despite facing challenges, as indicated by a negative price-to-earnings ratio of -0.984 and a close price of 0.255 EUR on April 28, 2026, Poxel’s market capitalization stands at 13,979,291 EUR. The company’s stock has experienced fluctuations, with a 52-week high of 0.83 EUR on June 1, 2025, and a low of 0.218 EUR on December 9, 2025. These financial metrics highlight the dynamic nature of the biotechnology sector and the inherent risks associated with clinical-stage companies.
Incorporated in 2009, Poxel S.A. continues to leverage its expertise in metabolic pathophysiology to develop groundbreaking treatments. With a robust pipeline and strategic partnerships, the company is well-positioned to address critical unmet needs in metabolic and liver diseases, offering hope to patients worldwide.
As Poxel S.A. progresses through its clinical trials and expands its therapeutic offerings, the company remains a key player in the biotechnology landscape, driven by its mission to improve patient outcomes through innovative drug development.
